{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T04:05:01Z","timestamp":1745208301948,"version":"3.40.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.127072","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:33:40Z","timestamp":1744115620000},"page":"127072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity"],"prefix":"10.1016","volume":"53","author":[{"given":"A.","family":"Mollo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Peri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lionetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Marrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.V.","family":"Mastrolia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Tintori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Indolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Astorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127072_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2025.127072_bb0010","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2025.127072_bb0015","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127072_bb0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.jp.7210599","article-title":"Neonatal varicella","volume":"21","author":"Sauerbrei","year":"2001","journal-title":"J Perinatol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.siny.2008.11.008","article-title":"Varicella in the fetus and newborn","volume":"14","author":"Smith","year":"2009","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.vaccine.2025.127072_bb0030","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1093\/infdis\/jiaa573","article-title":"Live attenuated varicella vaccine: prevention of varicella and of zoster","volume":"224","author":"Gershon","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0891-5520(05)70308-1","article-title":"Varicella-zoster virus. The virus","volume":"10","author":"Cohen","year":"1996","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.vaccine.2025.127072_bb0040","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.79.11.6969-6975.2005","article-title":"Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency","volume":"79","author":"Cohen","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0045","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s15010-023-02156-y","article-title":"Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns","volume":"52","author":"Steinmann","year":"2024","journal-title":"Infection"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.127072_bb0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0055","first-page":"14","article-title":"Herpes zoster: a review of clinical manifestations and management","author":"Patil","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2025.127072_bb0060","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/INF.0b013e31815cb239","volume":"27","author":"Rau","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127072_bb0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2025.127072_bb0070","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs","volume":"15","author":"Varela","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127072_bb0075","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127072_bb0080","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1542\/peds.2011-0017","article-title":"Varicella in infants after implementation of the US varicella vaccination program","volume":"128","author":"Chaves","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2025.127072_bb0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0031-3955(05)70212-1","article-title":"Varicella vaccine","volume":"47","author":"Chartrand","year":"2000","journal-title":"Pediatr Clin N Am"},{"key":"10.1016\/j.vaccine.2025.127072_bb0090","first-page":"281","article-title":"Varicella-zoster virus infections of the central nervous system \u2013 prognosis, diagnostics and treatment","volume":"71","author":"Grahn","year":"2015","journal-title":"J Inf Secur"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2025.127072_bb0095","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/522125","article-title":"The safety profile of varicella vaccine: a 10-year review","volume":"197","author":"Galea","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01816-24","article-title":"Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination","volume":"99","author":"Kennedy","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0105","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1016\/j.vaccine.2018.01.061","article-title":"Vaccination in immunocompromised host: recommendations of Italian primary immunodeficiency network centers (IPINET)","volume":"36","author":"Martire","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127072_bb0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127072_bb0115","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1093\/infdis\/jiy382","article-title":"Herpes Zoster Vaccines","volume":"218","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127072_bb0125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/pir.2017-0242","article-title":"Varicella Zoster Virus","volume":"40","author":"Blair","year":"2019","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.vaccine.2025.127072_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.mph.0000183272.30570.09","article-title":"Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review","volume":"27","author":"Mantadakis","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mpo.1186","article-title":"Noncutaneous varicella-zoster virus (VZV) infection with fatal liver failure in a child with acute lymphoblastic leukemia (ALL)","volume":"37","author":"M\u00fcller","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/08880010801938215","article-title":"Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia","volume":"25","author":"Matsuzaki","year":"2008","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/pbc.22759","article-title":"The controversy of varicella vaccination in children with acute lymphoblastic leukemia","volume":"58","author":"Caniza","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.vaccine.2025.127072_bb0150","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.vaccine.2018.01.038","article-title":"Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway","volume":"36","author":"Marchetti","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127072_bb0155","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0160","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0170","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/INF.0000000000001249","article-title":"Update on incidence of herpes zoster among children and adolescents after implementation of varicella vaccination, Antelope Valley, CA, 2000 to 2010","volume":"35","author":"Civen","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127072_bb0175","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","article-title":"The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination","volume":"28","author":"Civen","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127072_bb0180","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/infdis\/jit405","article-title":"Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009","volume":"208","author":"Weinmann","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7774\/cevr.2019.8.2.116","article-title":"A clinico-epidemiological multicenter study of herpes zoster in immunocompetent and immunocompromised hospitalized children","volume":"8","author":"Hwang","year":"2019","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2025.127072_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/infdis\/jiab501","article-title":"Widespread use of varicella vaccine does not reduce immunity to zoster of others","volume":"225","author":"Gershon","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0195","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","article-title":"Varicella vaccination - the global experience","volume":"16","author":"Wutzler","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127072_bb0200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bmt.1702119","article-title":"Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation","volume":"25","author":"Leung","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.vaccine.2025.127072_bb0205","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bmt.1705191","article-title":"Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience","volume":"37","author":"Berman","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.vaccine.2025.127072_bb0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13613-022-01002-y","article-title":"Neurologic outcome of VZV encephalitis one year after ICU admission: a multicenter cohort study","volume":"12","author":"Mirouse","year":"2022","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.vaccine.2025.127072_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2455","article-title":"Neurological complications of varicella zoster virus reactivation: prognosis, diagnosis, and treatment of 72 patients with positive PCR in the cerebrospinal fluid","volume":"12","author":"Lenfant","year":"2022","journal-title":"Brain Behav"},{"key":"10.1016\/j.vaccine.2025.127072_bb0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.vaccine.2025.127072_bb0225","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0230","doi-asserted-by":"crossref","first-page":"E288","DOI":"10.1002\/ajh.27038","article-title":"Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma","volume":"98","author":"Brady","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.vaccine.2025.127072_bb0235","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2025.127072_bb0240","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the Adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, Randomized Clinical Trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127072_bb0250","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s10875-021-01091-7","article-title":"Alternative approach to varicella zoster virus prevention in a child with lymphopenia","volume":"41","author":"Cortesi","year":"2021","journal-title":"J Clin Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500369X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500369X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T06:25:48Z","timestamp":1745130348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500369X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":50,"alternative-id":["S0264410X2500369X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127072"}}